GLPwatch

Exendin-4 Loaded Nanoparticles with a Lipid Shell and Aqueous Core Containing Micelles for Enhanced Intestinal Absorption.

J Biomed Nanotechnol · 2015

Last updated 2026-05-28

In this study, researchers created a special type of nanoparticle designed to deliver exendin-4, a GLP-1 drug, by mouth. The nanoparticles were 97.7% efficient at trapping the drug and improved its absorption in lab tests. In mice with diabetes, these nanoparticles lowered blood sugar levels, achieving 12.7% of the effect seen with injected exendin-4.

AI summary of the abstract below.

JournalJ Biomed Nanotechnol, 2015
Citations25
Relative citation ratio1.12
NIH percentile54
Molecules

Abstract

The purpose of this study was to formulate nanoparticles with an elaborate structure for oral delivery of exendin-4 using a simple preparation process. The nanoparticles possessed a mixed lipid shell and an aqueous core which contained drug-loaded micelles. Formulation was optimized by a central composite design and the structure of the nanoparticles was validated. The efficacy for delivery of exendin-4 was evaluated both in vitro and in vivo. The drug encapsulation efficiency of the nanoparticles reached 97.7%. The nanoparticles greatly enhanced the cellular uptake and transport of encapsulated exendin-4 in vitro. The in situ study showed that exendin-4 could be transported across the epithelium into intestinal capillaries, while the lipid materials largely remained in the epithelium. Pharmacodynamic studies in diabetic KKAy mice demonstrated that the exendin-4-loaded nanoparticles exhibited a marked hypoglycemia effect with a pharmacological availability of 12.7% after intestinal administration.

Verbatim abstract via PubMed 26349398 ↗